Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified)
分子別名（Synonym）
INSR,Insulin receptor,IR,CD220
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human Insulin R (28-944), His Tag (INR-H52Ha) is expressed from human 293 cells (HEK293). It contains AA His 28 - Lys 944 (Accession # P06213-2).
Predicted N-terminus: His 28
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus. The mature form of Insulin R a disulfide-linked heterotetramer composed of 2 alpha and 2 beta chains. Each α and β chain (partial fragment) has a calculated MW of 83.6 kDa and 22.8 kDa. The protein migrates as 120-130 kDa and 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
胰島素受體（INSR）也被稱為CD抗原CD220，它可以被切割成以下兩條鏈：胰島素受體亞基α和胰島素受體亞單位β。INSR是由2個(gè)α鏈和2個(gè)β鏈通過(guò)二硫鍵連接而成的四聚體。α鏈攜帶胰島素結(jié)合區(qū)，而β鏈攜帶激酶結(jié)構(gòu)域。與IGF1R形成雜交受體，該雜交體是由INSR的1條α鏈和1條β鏈以及IGF1R的1條a鏈和1個(gè)β鏈組成的四聚體。除了結(jié)合胰島素外，胰島素受體還可以結(jié)合胰島素樣生長(zhǎng)因子（IGFI和IGFII）。INSR的Isoform Short對(duì)IGFII結(jié)合具有更高的親和力。當(dāng)存在于與IGF1R的雜交受體中時(shí)，INSR結(jié)合IGF1。
關(guān)鍵字： 胰島素受體;Insulin R蛋白;CD220重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。